In his speech on the second day of the BioHabana 2022 International Congress, the official revealed that from four laboratories, Cuba could build 27 of those centers with a processing capacity of more than 25,000 samples to do diagnostic tests for SARS-CoV-2.
He said that thanks to the organization of the health services, intensive surveillance wards were created and beds were doubled for the care of suspected cases and patients with mild or moderate illness.
Portal highlighted the benefits of a scientific management system which, among other results, determined the circulating variants of the virus by means of genomic surveillance, and established the immune response in convalescents and in the rest of the population after the administration of vaccines.
The integrated work of all sectors, the active participation of the people and youths in particular, and the role played by science, not derived from the market but from the socialist system that prioritizes the human being, were strengths for the country, he remarked.
The minister referred to the benefits provided by drugs such as Nasalferon and Biomudulin-T with preventive effects, and other innovative drugs such as Jusvinza, Nomotuzumab and Itolizumab, which have shown recovery rates higher than 75 percent in severe patients, he said.
Finally, he praised the high vaccination rates achieved in Cuba, where more than 35,672,000 doses of the homegrown Abdala, Soberana 02 and Soberana Plus), and assured that it is the first country in the world to protect its citizens over two years of age massively way.
Since the outbreak of the pandemic, he added, 27 products have been developed to fight the virus, 18 of which have been authorized for emergency use by the Cuban regulatory authority.
The BioHabana 2022 Congress, which is running from Monday to Friday 29, brings together delegates and guests from 51 countries at Havana’s Convention Center.
The event will discuss 10 key topics, including medical technology and Industry 4.0, chronic inflammation, cancer and autoimmunity, agricultural biotechnology and brain diseases.